Alterations of cholesterol precursor levels in Alzheimer's disease

Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

Volumn 1801, Issue 8, 2010, Pages 945-950

  Kölsch, Heike ^a   Heun, Reinhard ^a,b   Jessen, Frank ^a   Popp, Julius ^a   Hentschel, Frank ^c   Maier, Wolfgang ^a   Lütjohann, Dieter ^a  

^a UNIVERSITY OF BONN   (Germany)

^b ROYAL DERBY HOSPITAL   (United Kingdom)

^c CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

Author keywords

Alzheimer disease; Cholesterol metabolism; Cholesterol synthesis; Desmosterol; Lanosterol; Lathosterol

Indexed keywords

APOLIPOPROTEIN E4; CHOLESTEROL; DESMOSTEROL; LANOSTEROL; LATHOSTEROL;

AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID LEVEL; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROTRANSMISSION; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; ALLELES; ALZHEIMER DISEASE; APOLIPOPROTEIN E4; CASE-CONTROL STUDIES; CHOLESTEROL; DESMOSTEROL; FEMALE; GENE FREQUENCY; HUMANS; LANOSTEROL; MALE; MIDDLE AGED; MODELS, BIOLOGICAL;

EID: 77953271764     PISSN: 13881981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbalip.2010.03.001     Document Type: Article

References (44)

1. Björkhem I., Lütjohann D., Diczfalusy U., Stahle L., Ahlborg G., and Wahren J. Cholesterol homeostasis in human brain: turnover of 24S-hydroperoxycholesterol and evidence for a cerebral origin of most of this oxysterol in the circulation. J. Lipid Res. 39 (1998) 1594-1600
2. Lütjohann D., Björkhem I., Locatelli S., Dame C., Schmolling J., Von Bergmann K., and Fahnenstich H. Cholesterol dynamics in the foetal and neonatal brain as reflected by circulatory levels of 24S-hydroxycholesterol. Acta Paediatr. 90 (2001) 652-657
3. Kölsch H., Heun R., Kerksiek A., Bergmann K.V., Maier W., and Lütjohann D. Altered levels of plasma 24S- and 27-hydroxycholesterol in demented patients. Neurosci. Lett. 368 (2004) 303-308
4. Notkola I.L., Sulkava R., Pekkanen J., Erkinjuntti T., Ehnholm C., Kivinen P., Tuomilehto A., and Nissinen A. Serum total cholesterol, apolipoprotein E ε4 allele, and Alzheimer's disease. Neuroepidemiol. 17 (1998) 14-20
5. Strittmatter W.J., Saunders A.M., Schmechel D., Pericak-Vance M., Enghild J., Salvesen G.S., and Roses A.D. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 1977-1981
6. Simons M., Keller P., De Strooper B., Beyreuther K., Dotti C.G., and Simons K. Cholesterol depletion inhibits the generation of β-amyloid in hippocampal neurons. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 6460-6464
7. Fassbender K., Simons M., Bergmann C., Stroick M., Lütjohann D., Keller P., Runz H., Kuhl S., Bertsch T., Von Bergmann K., Hennerici M., Beyreuther K., and Hartmann T. Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 5856-5861
8. Jick H., Zornberg G.L., Jick S.S., Seshadri S., and Drachman D.A. Statins and the risk of dementia. Lancet 356 (2000) 1627-1631
9. Haag M.D., Hofman A., Koudstaal P.J., Stricker B.H., and Breteler M.M. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J. Neurol. Neurosurg. Psychiatry 80 (2009) 13-17
10. Sparks L. Statins and cognitive function. J. Neurol. Neurosurg. Psychiatry 80 (2009) 1-2
11. Fassbender K., Stroick M., Bertsch T., Ragoschke A., Kuehl S., Walter S., Walter J., Brechtel K., Muehlhauser F., Von B.K., and Lütjohann D. Effects of statins on human cerebral cholesterol metabolism and secretion of Alzheimer amyloid peptide. Neurology 59 (2002) 1257-1258
12. Höglund K., Thelen K.M., Syversen S., Sjogren M., Von B.K., Wallin A., Vanmechelen E., Vanderstichele H., Lütjohann D., and Blennow K. The effect of simvastatin treatment on the amyloid precursor protein and brain cholesterol metabolism in patients with Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 19 (2005) 256-265
13. Arvanitakis Z., Schneider J.A., Wilson R.S., Bienias J.L., Kelly J.F., Evans D.A., and Bennett D.A. Statins, incident Alzheimer disease, change in cognitive function, and neuropathology. Neurology 70 (2008) 1795-1802
14. Rea T.D., Breitner J.C., Psaty B.M., Fitzpatrick A.L., Lopez O.L., Newman A.B., Hazzard W.R., Zandi P.P., Burke G.L., Lyketsos C.G., Bernick C., and Kuller L.H. Statin use and the risk of incident dementia: the Cardiovascular Health Study. Arch. Neurol. 62 (2005) 1047-1051
15. Zandi P.P., Sparks D.L., Khachaturian A.S., Tschanz J., Norton M., Steinberg M., Welsh-Bohmer K.A., and Breitner J.C. Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. Arch. Gen. Psychiatry 62 (2005) 217-224
16. Björkhem I., Miettinen T., Reihner E., Ewerth S., Angelin B., and Einarsson K. Correlation between serum levels of some cholesterol precursors and activity of HMG-CoA reductase in human liver. J. Lipid Res. 28 (1987) 1137-1143
17. Kempen H.J., Glatz J.F., Gevers Leuven J.A., d. van V., and Katan M.B. Serum lathosterol concentration is an indicator of whole-body cholesterol synthesis in humans. J. Lipid Res. 29 (1988) 1149-1155
18. Iivonen S., Hiltunen M., Alafuzoff I., Mannermaa A., Kerokoski P., Puolivali J., Salminen A., Helisalmi S., and Soininen H. Seladin-1 transcription is linked to neuronal degeneration in Alzheimer's disease. Neuroscience 113 (2002) 301-310
19. Solomon A., Leoni V., Kivipelto M., Besga A., Oksengard A.R., Julin P., Svensson L., Wahlund L.O., Andreasen N., Winblad B., Soininen H., and Björkhem I. Plasma levels of 24S-hydroxycholesterol reflect brain volumes in patients without objective cognitive impairment but not in those with Alzheimer's disease. Neurosci. Lett. 462 (2009) 89-93
20. Teunissen C.E., Lütjohann D., Von B.K., Verhey F., Vreeling F., Wauters A., Bosmans E., Bosma H., van Boxtel M.P., Maes M., Delanghe J., Blom H.J., Verbeek M.M., Rieckmann P., De B.C., Steinbusch H.W., and de V.J. Combination of serum markers related to several mechanisms in Alzheimer's disease. Neurobiol. Aging 24 (2003) 893-902
21. Folstein M.F., Folstein S.E., and McHugh P.R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12 (1975) 189-198
22. Mulder M., Ravid R., Swaab D.F., De Kloet E.R., Haasdijk E.D., Julk J., Van der Boom J., and Havekes L.M. Reduced levels of cholesterol, phospholipids, and fatty acids in cerebrospinal fluid of Alzheimer disease patients are not related to apolipoprotein E4. Alzheimer Dis. Assoc. Disord. 12 (1998) 198-203
23. Gottfries C.G., Karlsson I., and Svennerholm L. Membrane components separate early-onset Alzheimer's disease from senile dementia of the Alzheimer type. Int. Psychogeriatr. 8 (1996) 365-372
24. Wallin A., Gottfries C.G., Karlsson I., and Svennerholm L. Decreased myelin lipids in Alzheimer's disease and vascular dementia. Acta Neurol. Scand. 80 (1989) 319-323
25. Sarajarvi T., Haapasalo A., Viswanathan J., Makinen P., Laitinen M., Soininen H., and Hiltunen M. Down-regulation of seladin-1 increases BACE1 levels and activity through enhanced GGA3 depletion during apoptosis. J. Biol. Chem. 284 (2009) 34433-34443
26. Jurevics H., and Morell P. Cholesterol for synthesis of myelin is made locally, not imported into the brain. J. Neurochem. 64 (1995) 895-901
27. Chen H.W. Role of cholesterol metabolism in cell growth. Fed. Prod. 43 (1984) 126-130
28. Goodrum J.F., Brown J.C., Fowler K.A., and Bouldin T.W. Axonal regeneration, but not myelination, is partially dependent on local cholesterol reutilization in regenerating nerve. J. Neuropathol. Exp. Neurol. 59 (2000) 1002-1010
29. Koudinov A.R., and Koudinova N.V. Essential role for cholesterol in synaptic plasticity and neuronal degeneration. FASEB J. 15 (2001) 1858-1860
30. Mauch D.H., Nagler K., Schumacher S., Goritz C., Muller E.C., Otto A., and Pfrieger F.W. CNS synaptogenesis promoted by glia-derived cholesterol. Science 294 (2001) 1354-1357
31. Tint G.S., Seller M., Hughes-Benzie R., Batta A.K., Shefer S., Genest D., Irons M., Elias E., and Salen G. Markedly increased tissue concentrations of 7-dehydrocholesterol combined with low levels of cholesterol are characteristic of the Smith-Lemli-Opitz syndrome. J. Lipid Res. 36 (1995) 89-95
32. West R., Beeri M.S., Schmeidler J., Hannigan C.M., Angelo G., Grossman H.T., Rosendorff C., and Silverman J.M. Better memory functioning associated with higher total and low-density lipoprotein cholesterol levels in very elderly subjects without the apolipoprotein e4 allele. Am. J. Geriatr. Psychiatry 16 (2008) 781-785
33. Singh-Manoux A., Gimeno D., Kivimaki M., Brunner E., and Marmot M.G. Low HDL cholesterol is a risk factor for deficit and decline in memory in midlife: the Whitehall II study. Arterioscler. Thromb. Vasc. Biol. 28 (2008) 1556-1562
34. van den Kommer T.N., Dik M.G., Comijs H.C., Fassbender K., Lütjohann D., and Jonker C. Total cholesterol and oxysterols: early markers for cognitive decline in elderly?. Neurobiol. Aging 30 4 (2009) 534-545
35. Anstey K.J., Lipnicki D.M., and Low L.F. Cholesterol as a risk factor for dementia and cognitive decline: a systematic review of prospective studies with meta-analysis. Am. J. Geriatr. Psychiatry 16 (2008) 343-354
36. Carlsson C.M., Gleason C.E., Hess T.M., Moreland K.A., Blazel H.M., Koscik R.L., Schreiber N.T., Johnson S.C., Atwood C.S., Puglielli L., Hermann B.P., McBride P.E., Stein J.H., Sager M.A., and Asthana S. Effects of simvastatin on cerebrospinal fluid biomarkers and cognition in middle-aged adults at risk for Alzheimer's disease. J. Alzheimers. Dis. 13 (2008) 187-197
37. Rockwood K., Kirkland S., Hogan D.B., MacKnight C., Merry H., Verreault R., Wolfson C., and McDowell I. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch. Neurol. 59 (2002) 223-227
38. Wolozin B., Kellman W., Ruosseau P., Celesia G.G., and Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch. Neurol. 57 (2000) 1439-1443
39. Li G., Higdon R., Kukull W.A., Peskind E., Van Valen M.K., Tsuang D., Van Belle G., McCormick W., Bowen J.D., Teri L., Schellenberg G.D., and Larson E.B. Statin therapy and risk of dementia in the elderly: a community-based prospective cohort study. Neurology 63 (2004) 1624-1628
40. Zhou B., Teramukai S., and Fukushima M. Prevention and treatment of dementia or Alzheimer's disease by statins: a meta-analysis. Dement. Geriatr. Cogn. Disord. 23 (2007) 194-201
41. Sparks D.L., Lemieux S.K., Haut M.W., Baxter L.C., Johnson S.C., Sparks L.M., Sampath H., Lopez J.E., Sabbagh M.H., and Connor D.J. Hippocampal volume change in the Alzheimer Disease Cholesterol-Lowering Treatment trial. Cleve Clin. J. Med. 75 Suppl 2 (2008) S87-S93
42. Pfizer INC, An 80-Week, randomized, multi-center, parallel-group, double-blind study of the efficacy and safety of Atorvastatin 80 mg plus an acetylcholinesterase inhibitor versus an acetylcholinesterase inhibitor alone in the treatment of mild to moderate Alzheimer's disease, A2581078 (2008) online 10-9-2009, http://www.clinicalstudyresults.org/drugdetails/viewfile.php?study_name=Protocol+No.+A2581078&file=ttp%3A%2F%2Fpdf.clinicalstudyresults.org%2Fdocuments%2Fcompany-study_4374_0.pdf.
43. Rosen W.G., Mohs R.C., and Davis K.L. A new rating scale for Alzheimer's disease. Am. J. Psychiatry 141 (1984) 1356-1364
44. Thelen K.M., Falkai P., Bayer T.A., and Lütjohann D. Cholesterol synthesis rate in human hippocampus declines with aging. Neurosci. Lett. 403 (2006) 15-19